Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $3.92 Million Position in Zimmer Biomet Holdings Inc (ZBH)

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 3.6% in the 4th quarter, Holdings Channel reports. The firm owned 31,391 shares of the medical equipment provider’s stock after purchasing an additional 1,096 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Zimmer Biomet were worth $3,921,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ZBH. Longview Partners Guernsey LTD raised its position in Zimmer Biomet by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares during the last quarter. Koch Industries Inc. raised its position in Zimmer Biomet by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after purchasing an additional 1,038,674 shares during the last quarter. Alyeska Investment Group L.P. raised its position in Zimmer Biomet by 249.3% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock worth $119,417,000 after purchasing an additional 727,925 shares during the last quarter. Jana Partners LLC raised its position in Zimmer Biomet by 16.6% during the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after purchasing an additional 662,497 shares during the last quarter. Finally, American Century Companies Inc. raised its position in Zimmer Biomet by 14.7% during the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after purchasing an additional 612,044 shares during the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently issued reports on the company. Goldman Sachs Group raised Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 target price for the company in a research report on Tuesday, December 19th. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $120.00 to $168.00 in a research report on Wednesday, January 31st. Canaccord Genuity reissued a “hold” rating and issued a $132.00 price objective on shares of Zimmer Biomet in a research report on Friday, January 5th. Robert W. Baird reissued a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, BMO Capital Markets reissued a “buy” rating and issued a $142.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $141.67.

Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $116.39 on Friday. Zimmer Biomet Holdings Inc has a 12-month low of $108.03 and a 12-month high of $133.49. The company has a market capitalization of $23,570.00, a PE ratio of 12.90, a P/E/G ratio of 2.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, meeting analysts’ consensus estimates of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The business had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same period in the previous year, the company posted $2.14 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. equities analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s payout ratio is 10.64%.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/02/10/mitsubishi-ufj-kokusai-asset-management-co-ltd-has-3-92-million-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit